NCT03900975 is a clinical trial in Vulvar Paget's Disease, sponsored by University Hospital, Ghent.

Who is sponsoring NCT03900975?

NCT03900975 is sponsored by University Hospital, Ghent.

What condition does NCT03900975 study?

NCT03900975 studies Vulvar Paget's Disease.

Is NCT03900975 still recruiting?

NCT03900975 is currently completed. Last updated 10 November 2020.

Last reviewed 2020-11-10 · How we verify

NCT03900975

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vulvar Paget Disease

Completed Last updated 10 November 2020

What this trial tests

trial in Vulvar Paget's Disease in 8 participants. Completed in 31 July 2020.

Timeline

25 September 2018

Primary endpoint
30 June 2020

31 July 2020

Quick facts

Lead sponsor	University Hospital, Ghent
Status	Completed
Study type	OBSERVATIONAL
Enrollment	8
Start date	25 September 2018
Primary completion	30 June 2020
Estimated completion	31 July 2020
Sites	1 location across Belgium

Conditions studied

Vulvar Paget's Disease — all drugs for Vulvar Paget's Disease →

Sponsor

University Hospital, Ghent

Who can join

Adults 18 to 99, female only, with Vulvar Paget's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study only women with vulvar paget disease will be included and will be analysed retrospectively. Vulvar paget disease patients are frequently treated with surgical resection of the affected tissue. During a surgical treatment surgical margins are frequently positive. Recidives are seen frequently after surgical treatment or the development of other pathologies such as vulvar carcinoma. In this study the outcome of the vulvar paget disease will be analysed and compared between the participants. It's primary goal is to create a better view on the outcome and the prognosis to prevent e.g. complications in the future.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Ghent trials

Trials by the same sponsor.

NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03900975 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
Last refreshed: 10 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03900975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing